Abstract:6646 Background: Extranodal peripheral T-cell lymphoma arising in facial midline has unique clinicopathologic features, the optimal treatment and prognostic factors remain unclear. Methods: 112 patients with pathologically confirmed nasopharyngeal/nasal type peripheral T cell lymphomas were included from April, 1994 to Dec, 2003, 39 patients were identified as CD56(+) NK/T cell lymphoma. Median pre-treatment disease history(PTDH) was 4 months, male/female ratio was 3.0:1, with a median age of 46 years. 91.1% of the patients were staged as Ann Arbor I and II diseases. International Prognostic Indices were < 2 scores in 78.8% of the patients. Most patients underwent combined chemo and radiotherapy, 32 patients underwent chemotherapy only. Chemotherapy was mainly in CHOP like regimens(median 5 cycles). High energy photon/electron rays were used for radiotherapy(median curative dose 54Gy). Results: Median follow-up time for survived patients was 42 months. Chemotherapy achieved a CR rate of 34.4% as initial treatment, the CR rate after primary treatment was 65.1%. Median time to disease progression (TTP) was 11 months, local control rate for stage I and II tumors was 50.5%. There were evidences indicating systemic relapse in > 30% of the patients. Radiation therapy showed a positive correlation with local control and TTP. The number of chemo cycles was positively correlated with TTP, but not with local control. Progress-free survival and overall survival rates were 38.8% and 52.4% at 3 years, and 34.9% and 44.8% at 5 years, respectively. In univariate analysis survival favorable factors included PTDH > 2 months, earlier clinical stage, non-NK/T lymphoma diagnoses, no skin invasion, lower risk IPI, CR after initial chemotherapy and radiotherapy. In multivariate analysis, PTDH > 2 months, non-NK/T lymphoma diagnoses, CR after initial chemotherapy, and radiotherapy were survival favorable prognostic factors. Conclusions: CD56(+) NK/T lymphoma can be more aggressive than other nasopharyngeal/nasal type peripheral T-cell lymphomas. Combined chemo and radiotherapy as principal treatments need improvement to increase remission rates so as to improve survival. No significant financial relationships to disclose.

Dynamic changes of T cell subtypes of local-regional advanced nasopharyngeal carcinoma during chemo-radiotherapy and follow up

Changes in C-Kit Expression Levels During the Course of Radiation Therapy for Nasopharyngeal Carcinoma

CD4+CD25high Regulatory Cells in Peripheral Blood of NSCLC Patients

Treatment-Related Lymphopenia is Possibly a Marker of Good Prognosis in Nasopharyngeal Carcinoma: a Propensity-Score Matching Analysis

Long-term results of concurrent chemoradiotherapy for T3/T4 locally advanced nasopharyngeal carcinoma.

Changes in plasma EBV-DNA and immune status in patients with nasopharyngeal carcinoma after treatment with intensity-modulated radiotherapy

Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: Study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA

Curative Effects and Late Phase Reactions of Nasopharyngeal Carcinoma Treated with Radiotherapy in 246 Cases

Increase in circulating Foxp3+CD4+CD25high regulatory T cells in nasopharyngeal carcinoma patients

Variation of CD4~+CD25~(high)Treg in Peripheral Blood of Patients with Nasopharyngeal Carcinoma

Treatment result of radiotherapy alone for patients with early stage nasopharyngeal carcinoma

Clonal dynamics of tumor-infiltrating T-cell receptor beta-chain repertoires in the peripheral blood in response to concurrent chemoradiotherapy for Epstein–Barr virus-associated nasopharyngeal carcinoma

The Changes of Gene Express Profile of Nasopharyngeal Carcinoma Tissue Before and after the Radiotherapy of 2 Gy

Concurrent chemoradiotherapy followed by adjuvant chemotherapy for locally advanced nasopharyngeal carcinoma

Influence of Treg and Th17 Cell in the Tumor Microenvironment on Progression and Prognosis of Nasopharyngeal Carcinoma

Nasopharyngeal/Nasal Type Peripheral T-Cell Lymphomas: Long-Term Outcomes And Prognostic Analysis Of 112 Cases In Southern China.

A Study of the Combined Treatment Strategy for Patients with Nasopharyngeal Carcinoma Based on the Analysis of the Treatment Results from 749 Cases

Systemic Chemotherapy and Sequential Locoregional Radiotherapy in Initially Metastatic Nasopharyngeal Carcinoma: Retrospective Analysis with 821 Cases

1108OChemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: A randomized, open-label, phase III trial

Individualized Concurrent Chemotherapy for Patients with Stage III–IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy